Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced promising preliminary results from their ASCEND study, focusing on a new ...

Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, evaluating the investigational therapy ...

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab ...

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Results from the Phase III ASCEND trial (NCT05882877) showed rocatinlimab maintained long-term efficacy with a favorable ...

Across the Phase 3 ROCKET program including ASCEND, the incidence of gastrointestinal ulceration events with rocatinlimab to date is less than 1 per 100 patient-years. The ASCEND study is ongoing and ...

William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects ...

Amgen & Kyowa Kirin announce positive results from rocatinlimab phase 3 ASCEND study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Wednesday, Sept ...

On September 9, Seema Shah, Chief Global Strategist at Principal Asset Management, appeared on CNBC for an interview to ...

Amgen (AMGN) stock in focus as the company and Kyowa Kirin (KYKOF) report Phase 3 data showing their atopic dermatitis drug, ...

Suddenly one obesity asset has come to define Amgen but executives see a fuller portfolio that will bring the big biotech ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...